Ototoxicitysecondary totheadministration of thechemotherapeutic agent oxaliplatin is uncommon. We report a case of unilateral hearing loss that occurred immediately after the infusion of a single dose of oxaliplatin in a 70year-old woman who was undergoing postoperative chemotherapy for rectal adenocarcinoma. To the bestof our knowledge, no such case has been previously reported in the literature. The hearing loss in our patient was severe enough to limit her daily activities, and she experienced only minimal improvement during the next 2 years of follow-up.
Introduction
Ototoxicity related to the use of platinum-containing chemotherapeutic regimens has been well documented. However, the relationship between ototoxicity and the newer genera tion ofplatinum-derived agents, including oxaliplatin, is not as well established in the litera ture. 1,2 Oxaliplatin-containing chemotherapeutic regimens are ind icated bo th to treat advanced colorectal cancer and to red uce the risk of recurrence in patients with resected stage III disease.
Fewer than 1% of patients who receive oxaliplatin develop ototoxicity characterized by hearing 10ss.3We report a unique case of acute unilateral ototoxicity following a single intravenous infusion of oxaliplatin, and we discuss the implications of this adverse event. From 
Case repo rt
A 70-year-o ld woman with an audiometrically confirmed, moderate, high-frequencysensorineuralhearing loss bilatera lly (figur e 1) presented with intermittent bright-red rectal bleeding. Th e clinical evaluation indicated that she had at least stage III adenocarcinoma of the rectum. The patient was assigned to receive preoperative chemotherapy with capecitabine plus pelvic radiation therapy. Afterward, she underwent a laparoscopic colectomy with sampling of 191ymph nodes; 5 of these nodes were found to be cancerous. She was then scheduled to begin combination chemotherapy with capecitabine plus oxaliplatin. Immediately before the administration of the first infusion ofoxaliplatin, the patient was premedicated with intravenous ondansetron, dexamethasone, calcium,and magnesium. Next, oxaliplatin at 85 mg/m-was infused through a left forearm vein over 2 hours. Im mediately after the infusion, th e patien t experienced severe pain in the left arm, face, and jaw, and she repo rted difficulty opening and closing her mo uth. She also reported the onset of left-sided hearing loss. The pain and difficulty with jaw movement resolved spontaneously within 24 hours, but the hearing loss persisted. A new audiogram obtained 2 weeks postinfusion showed a remarkably severe, flat hearing loss in the left ear (figure 2). Evaluation with magnetic resonance imaging, electronystagmography,and auditory brainstem response testing did not reveal the source of the hearing loss. However, the results ofelectrocochleography identified the cochlea as the source of the ototoxicity. No other obvious cause of the acute hearing loss was detected.
Repeat audiometry obtained 5 months postinfusion showed that the severe hearing loss in the left ear had not abated (figur e 3). At 9 months postinfusion, some improvement was seen on the left (figure 4), bu t the change was not clinically significant, and th e hearing loss continued to lim it the patient's activity.Two months later, the patie nt was reevaluated, but she declined to RADIESSE®Voice and RADIESSE®Voice Gel .Implants for vocal fold augmentation I00IESSE® Voice BioForm Medical, Inc. I www.radiesse-voice.comlent@bioformmedical.comINorth America: 1-866-862-1211 I Europe: +31-0-162-474-800
RADIESSE Voice Products
The RADIESSE Voice injectable implant contains synthetic Calcium Hydroxylapatite (CaHA) microspheres, which have a diameter of 25-45 micron , suspended in an aq ueo us resorbable carrier gel. The product is injectable th rough a 25-gauge needle. RADIESSE Voice implant provides vocal fold augmentation with results that typically lasts 1 year.
The RADIESSE Voice Gel injectable impl an t contains synthe tically derived poly mers, with no Ca HA microspheres, and it is suitable for short term vocal fold augme ntation in patients where reversible ner ve dam age is suspected, or in patient s wishing a shor t term augme ntation before deciding to have a lon g term augmentation don e with th e RADI ESSE Voice impl ant.
RADIESSEVoice and RADIESSE Voice Gel implants are sold with either a malleable transoral needle or a non-c oring perc utaneous needle.
Unique mechanism ofaction
Over time the RADIESSE Voice implant carrier gel is resorbed and the Calcium Hydr oxylapat ite particle s suppo rt in-growth of new collagen. The durable Calciu m Hydroxylapatite microsphere s degra de slowly over years for a long-lasting effect. The implant remains soft after inject ion and does not ossify.
In clin ical testi ng and ro utine clin ical use for over 6 years, no implant migration or evide nce of gra nu loma forma tion has been observed. 
Injection techniques
RADlESSE products can be injected through a 25-gauge needle in the ope rating room or in the office using a trans-thyroid cartilage, tr ans-cricothyroid memb rane or thyrohyoid approach-3. 
Thyrohyoid injection technique

Clinically proven results
• Proven effective -in clinical testing with 12 months follow up, the major ity of patients treated with the RADlESSE Voice implant report ed that thei r voice was greatly or significantly imp roved.' • Proven safe -no granuloma formation or major complications have been reported.' • Proven long-lasting -results typically last more than 12 months':', 
Discussion
Oxaliplatin is a third-generation platinum derivative that has become an int egral parto fvariouschemotherapeutic regimens for colorectal canc er. Neurotoxicity is the most important (and often dose -limited) adverse event associated with its use.' Oxaliplatin induces two distinct types of clinical neural dysfunction:
• an acute syndrome that is characterized by transient sensory symptoms, such as perioral pare sthe sias or dysesth esias, and • a per sistent sen sor y neurotoxicit y that is characterized by progressive and cumulative deficits.
It is uncl ear wh ether the acute and persistent neuropathies are related . Th e acute neurotoxiciti es may be related to th e chelation of calcium ion s by th e oxalate released from oxaliplatin and their subsequent untoward effects on the sodium channels in the neural m embran e and synap ses."Acute neurotoxicitie s have been reported in 92% of all patients who are exposed to oxaliplatin." Fi gure 2. Two weeksafter the infusion ofoxalipiatin chemothempy, audiometry demonstrates the remarkabty severe, flnt hearing loss ill the left ear.
They tend to occur immediately after th e ad m in istration of th e drug, as occurred in our case, and they typic ally resolve rap idly.
The per sistent neural adverse events,which have been reported to occur in 10 to 15% of patients, appear to occur seconda ry to th e accumulation of platinum in dorsal nerve root gang lia.' Th ey occur later than the acute complications-usually after a cumulative do se of 780 to 850 m g/nr ' has been ad m inistered. Th ese neuropathies are also slower to resolve, as th e median time to recovery is about 13 weeks."
To the best of our knowledge, no case of acute ototoxicity following th e infu sion of a single dose of oxalip latin has been previousl y reported in the literature.':' Our case was unique-not only because th e neurotoxic event occurred acutely and remained persistent, but also becaus e the hearing loss was severe enough to interfere with th e patient's activities of daily living (grade 3, according to the Commo n Terminology Criteria for Adverse Events, version 3).
It is also of inte rest that our pat ient received oxaliplatin in th e left arm and her neurologic sympto ms were limited to the left side . Th ere is no explana tion for this ph enomenon .
In a recent study o n a guinea pig model, Hellberg et al showed that the degree of cochlear uptake of platinum compounds correlates with hearing loss." Cisp lati n uptake was fivefold higher th an oxalip latin uptake when equimolar treatments were given intravenously. We suspect that the cause of the hearing loss in our patient might have been an idiopathic inc rease in cochlear uptake. The additional occurrence ofan injury to cranial nerve VIII in our patient highlights the need for physicians to be aware ofprevious VIIIrh nerve dam age before exposing a patient to a potentially neurotoxic agent.
Finally, th e persistence of our patient's ototoxicity supports the contention that even though the underlying pathophysiologic mechanisms of acute and per sistent neurotoxicity may differ, a linkage between them may exist.
